Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II safety and efficacy study of catumaxomab after neoadjuvant chemotherapy and curative gastric cancer resection
2006-002727-16Phase 2Completed
- Sponsor
- Fresenius
- Start
- Nov 2006
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of catumaxomab in gastric adenocarcinoma, sponsored by Fresenius. Primary endpoint: Rate of specific postoperative complications within 30 days after surgery. Started Nov 2006; status: completed.
02
Drugs
catumaxomab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2006-002727-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002727-16.